MedTrace Logo

Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers

NCT00777361 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2010-11-18

No results posted yet for this study

Summary

This study is being performed in order to learn more about a new drug (possible as treatment for people with Alzheimer's Disease and other conditions with cognitive dysfunction (memory and attention problems)) and how it is handled by the body by giving the drug to healthy volunteers with different genotypes.

Conditions

Interventions

DRUG

AZD3480

Iv single dose, 4-hour infusion of 25 mg

DRUG

AZD3480

Oral solution single dose of 50 mg

Sponsors & Collaborators

Principal Investigators

  • Björn Paulsson, MD, PhD · AstraZeneca Södertälje, Sweden

  • Tim Mant, Prof · Quintiles Drug Research Unit @ Guy´s Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00777361 on ClinicalTrials.gov